Advexin cancer therapy featured in Conquest magazine
10/15/2004 Lab Business Week editors Lab Business Week Introgen Therapeutics, Inc., (INGN) announced that its Advexin program has been featured in Conquest magazine, the quarterly magazine published by The University of Texas M. D. Anderson Cancer Center. A feature article about M. D. Anderson's pioneering research in gene therapy highlighted Introgen's lead product Advexin. Also profiled were two lung cancer patients who had previously failed conventional therapies and then received combination treatments with Advexin therapy. These two patients recently celebrated their 5-year anniversary. Previously, M. D. Anderson profiled another lung cancer patient from the same Advexin trial who also celebrated her 5-year survival after failing conventional treatments. In addition to the Advexin program, the article also discussed two other cancer therapies from Introgen that are currently being tested at M. D. Anderson. One is the phase I clinical development of INGN 401, Introgen's systemically delivered nanoparticle tumor suppressor therapy. INGN 401 uses the FUS-1 gene, a gene frequently altered or missing in the development of many solid tumors. Encouraging preliminary data from this trial was discussed in Introgen's recently held quarterly conference. The phase I trial is treating patients with refractory stage IV non-small-cell lung cancer patients who typically have limited survival of approximately six months. Five of six patients are still alive 11-15 months after treatment with INGN 401. Also mentioned in the article is Introgen's clinical trial testing Advexin as an oral rinse, or mouthwash, for precancerous oral lesions. This trial uses "topical gene therapy to treat patients [...]